Novo, MIT develop oral biologic delivery device

A team including Massachusetts Institute of Technology and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) scientists have developed an ingestible pill-sized device that can deliver drugs, including insulin, directly to the gastric mucosa.

The device -- called a self-orienting millimeter-scale applicator (SOMA) -- could overcome challenges to oral delivery of biologics, which include degradation in the gastrointestinal tract and low rates of absorption from the lumen of the GI tract...